Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PDE5 Inhibitors Clear all
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction

NCT03067987
View directory record Official record
Conditions
Vasculogenic Erectile Dysfunction
Interventions
Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.
Device
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 12, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

LiSWT for Men With Erectile Dysfunction

NCT06469775
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Low intensity shock wave, Control
Device · Combination Product
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

NCT01275404
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls, Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PDE Inhibitors in DMD Study (Acute Dosing Study)

NCT01580501
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Tadalafil and Sildenafil
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
7 Years to 15 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 12, 2026, 2:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.

NCT02757807
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Utilization of Serenita for Relaxation
Behavioral
Lead sponsor
Eco Fusion
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 12, 2026, 2:19 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

NCT00931528
View directory record Official record
Conditions
Prostate Cancer, Sexual Dysfunction
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
183
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment

NCT03229889
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Cialis 5Mg Tablet, Flomax 0.4Mg Capsule, Cialis + Flomax, Placebo
Drug · Combination Product
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 99 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901
View directory record Official record
Conditions
Sickle Cell Disease, Priapism
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 12, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RTN-001, Matching placebo control
Drug
Lead sponsor
Retension Pharmaceuticals. Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
24
States / cities
Alexander City, Alabama • Tucson, Arizona • San Jose, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT03496207
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Sotatercept, SOC
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

NCT05684289
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 12, 2026, 2:19 PM EDT
Completed No phase listed Observational Results available

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

NCT01131104
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
PDE5 Inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Los Altos, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

NCT01063855
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Placebo, Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 12, 2026, 2:19 PM EDT
Withdrawn No phase listed Observational

Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

NCT05458232
View directory record Official record
Conditions
Sarcopenia
Interventions
Tadalafil 5mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 12, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT00867815
View directory record Official record
Conditions
Anterior Ischemic Optic Neuropathy
Interventions
Diagnostic procedures
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
11
States / cities
Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

NCT00455715
View directory record Official record
Conditions
Schizophrenia
Interventions
Sildenafil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 12, 2026, 2:19 PM EDT
Active, not recruiting No phase listed Observational

TrEatment Approach in the Multimodal Era Registry

NCT05629052
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Pulmonary endarterectomy, Balloon pulmonary angioplasty, Pulmonary hypertension (PH)-specific medication
Procedure · Drug
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
San Diego, California • Evanston, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 12, 2026, 2:19 PM EDT
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

NCT00549302
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

NCT00708916
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
CC-10004
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 12, 2026, 2:19 PM EDT